- Home
- EFOR vs ETON Comparison
EFOR vs ETON Comparison
Compare EFOR & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EFOR | ETON |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | United States |
| Employees | 2800 | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 749.5M | 872.7M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | EFOR | ETON |
|---|---|---|
| Price | $30.56 | $45.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $39.33 |
| AVG Volume (30 Days) | ★ 1.1M | 520.5K |
| Earning Date | N/A | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.05 |
| Revenue | N/A | ★ $79,950,000.00 |
| Revenue This Year | N/A | $40.90 |
| Revenue Next Year | N/A | $47.23 |
| P/E Ratio | ★ N/A | $902.80 |
| Revenue Growth | N/A | ★ 104.94 |
| 52 Week Low | $16.90 | $14.27 |
| 52 Week High | $30.71 | $50.18 |
Technical Indicators
Market Signals| Indicator | EFOR | ETON |
|---|---|---|
| Relative Strength Index (RSI) | 79.46 | 61.39 |
| Support Level | $16.94 | $15.77 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 1.54 | 2.66 |
| MACD | 1.13 | 0.07 |
| Stochastic Oscillator | 89.86 | 61.32 |
Price Performance
Historical ComparisonAbout EFOR Everforth Inc. Common Stock
Everforth Inc is a technology and digital engineering company that helps organizations adapt, innovate, and thrive in a world of constant change. It has six solution areas: AI & data, cloud and infrastructure, digital engineering, customer experience, cybersecurity, and enterprise platforms - accelerate time to value for commercial and federal clients.
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.